Doctors Weigh Pros and Cons of Prescribing Hot-Button Alzheimer's Drug
KHN - 7/9/21
Doctors explaining the pros and cons of Aduhelm won’t have a definitive answer. “On an individual basis, it will be absolutely impossible to predict,” said Dr. Allan Levey, director of the Goizueta Alzheimer’s Disease Research Center at Emory University.
Jaffar Khan Named Interim Chair of Neurology
Emory - 7/1/21
Jaffar Khan, MD, is serving as interim chair of the Department of Neurology in the Emory University School of Medicine. Khan is associate professor of neurology and serves as assistant dean and vice-chair for Medical Education. He assumed the interim chair role in late May.
Raul Nogueira Honored with Albert E. Levy Award for Excellence in Scientific Research
Emory - 6/15/21
Neurologist Raul Nogueira is this year’s recipients of the Albert E. Levy Award for Excellence in Scientific Research, established to recognize the contributions of Emory faculty members to the advancement of scientific knowledge.
"Flicker" Treatment Aims to Slow Alzheimer's Disease with Lights and Sounds
Emory - 6/15/21
Emory and Georgia Tech investigators recently reported the results of the first human feasibility study of the “Flicker” treatment, a non-pharmaceutical approach aimed at slowing Alzheimer’s disease.
A Living Laboratory: Monitoring Alzheimer’s Disease in its Earliest Stages
Advancing Your Health - 6/14/21
”I get so full and so excited to say I’m part of a trailblazing team that’s going to be the benchmark for something that’s going to happen all over the world,” Williams says. “You guys need to put a picture of us on the wall out there and put our names beside it because we’re the first group.”
Georgia Families Hope Alzheimer’s Drug Helps Loved Ones
US News & World Report - 6/12/21
The U.S. Food and Drug Administration recently granted accelerated approval for the use of aducanumab, sold under the brand name Aduhelm and developed by Biogen and a Japanese company, for the treatment of Alzheimer’s, a progressive disease that affects 6.2 million people in the nation.
Georgia Families Hope Alzheimer’s Drug Helps Loved Ones
AJC - 6/11/21
The U.S. Food and Drug Administration recently granted accelerated approval for the use of aducanumab, sold under the brand name Aduhelm and developed by Biogen and a Japanese company, for the treatment of Alzheimer’s, a progressive disease that affects 6.2 million people in the nation.
Out of My Mind: Advances in Brain Tech Spur Calls for 'Neuro Rights'
Thomson Reuters Foundation - 3/29/21
But warnings of "science-fiction scenarios" of for-profit mind control are overblown for a line of research that is still so young, said Karen Rommelfanger, director of the neuroethics program at Emory University in Atlanta.
Prognostic Factors Nullify Positive Link Between Race, Survival in ALS
Healio - 1/11/21
Black patients with ALS experienced a greater median survival than white patients in a large, single-center study, though researchers found no independent association between race and survival after adjusting for ALS prognostic factors.
Genuity Science and Emory University Announce Key Research Agreement Collaboration Designed to Speed Insights into Major Neurodegenerative Diseases
PR Newswire - 1/7/21
Genuity Science, a U.S.-headquartered data, analytics and insights organization, today announces an agreement with one of the world’s leading medical research institutions, Emory University.